Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ.

Biochem J. 2005 Aug 15;390(Pt 1):125-36.

2.

Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.

Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, Harris JL, Ellis V.

Biochem J. 2010 Feb 9;426(2):219-28. doi: 10.1042/BJ20091448.

PMID:
20015050
3.

Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.

Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C.

J Mol Biol. 2005 Mar 11;346(5):1335-49.

PMID:
15713485
4.

Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.

Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P.

FEBS Lett. 2005 Mar 28;579(9):1945-50.

5.

Proteolytic activation of pro-macrophage-stimulating protein by hepsin.

Ganesan R, Kolumam GA, Lin SJ, Xie MH, Santell L, Wu TD, Lazarus RA, Chaudhuri A, Kirchhofer D.

Mol Cancer Res. 2011 Sep;9(9):1175-86. doi: 10.1158/1541-7786.MCR-11-0004.

6.

Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.

Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P.

J Biol Chem. 2003 Sep 19;278(38):36341-9.

8.

Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.

Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y, Kataoka H.

Cancer Sci. 2007 Apr;98(4):491-8.

9.

Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Tervonen TA, Belitškin D, Pant SM, Englund JI, Marques E, Ala-Hongisto H, Nevalaita L, Sihto H, Heikkilä P, Leidenius M, Hewitson K, Ramachandra M, Moilanen A, Joensuu H, Kovanen PE, Poso A, Klefström J.

Oncogene. 2016 Apr 7;35(14):1832-46. doi: 10.1038/onc.2015.248.

PMID:
26165838
10.

Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.

Kirchhofer D, Yao X, Peek M, Eigenbrot C, Lipari MT, Billeci KL, Maun HR, Moran P, Santell L, Wiesmann C, Lazarus RA.

J Biol Chem. 2004 Sep 17;279(38):39915-24.

11.

Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.

Gray K, Elghadban S, Thongyoo P, Owen KA, Szabo R, Bugge TH, Tate EW, Leatherbarrow RJ, Ellis V.

Thromb Haemost. 2014 Aug;112(2):402-11. doi: 10.1160/TH13-11-0895.

PMID:
24696092
13.

TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.

Hashimoto T, Kato M, Shimomura T, Kitamura N.

FEBS J. 2010 Dec;277(23):4888-900. doi: 10.1111/j.1742-4658.2010.07894.x.

14.

Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells by hepatocyte growth factor signaling in mice.

Hsu YC, Huang HP, Yu IS, Su KY, Lin SR, Lin WC, Wu HL, Shi GY, Tao MH, Kao CH, Wu YM, Martin PE, Lin SY, Yang PC, Lin SW.

Hepatology. 2012 Nov;56(5):1913-23. doi: 10.1002/hep.25773.

PMID:
22505209
15.
16.

Pro-urokinase-type plasminogen activator is a substrate for hepsin.

Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D.

J Biol Chem. 2006 Oct 13;281(41):30439-46.

17.

Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.

Franco FM, Jones DE, Harris PK, Han Z, Wildman SA, Jarvis CM, Janetka JW.

Bioorg Med Chem. 2015 May 15;23(10):2328-43. doi: 10.1016/j.bmc.2015.03.072.

PMID:
25882520
18.

Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.

Kirchhofer D, Lipari MT, Santell L, Billeci KL, Maun HR, Sandoval WN, Moran P, Ridgway J, Eigenbrot C, Lazarus RA.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5306-11.

19.

Hepsin and prostate cancer.

Wu Q, Parry G.

Front Biosci. 2007 Sep 1;12:5052-9. Review.

PMID:
17569629
20.

Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V.

J Biol Chem. 2008 Nov 7;283(45):30576-84. doi: 10.1074/jbc.M802312200.

Items per page

Supplemental Content

Support Center